Mass tort firms are navigating two competing realities: (1) claimant volume can surge overnight, and (2) eligibility often hinges on detailed exposure, product usage, medical timelines, and documentation that don’t fit neatly into a single “yes/no” form. That mismatch has historically forced firms into expensive tradeoffs, either slow, manual review or fast triage that risks inconsistent screening and downstream fallout.
AI is changing that equation. Not by replacing attorneys, but by compressing the time between lead capture and defensible eligibility decisions, while making screening more consistent and auditable.
Below is a practical view of what’s changing, where AI fits, and how to think about quality control so your eligibility pipeline gets faster without becoming fragile.
1) From “document review” to “case review”: what’s actually being automated
Traditional litigation tech conversations often focus on eDiscovery and technology-assisted review (TAR). Courts have recognized predictive coding / computer-assisted review as an acceptable approach in appropriate matters, famously in Da Silva Moore v. Publicis Groupe, which helped normalize machine-assisted review as a cost-control tool in high-volume discovery.
Mass tort intake and eligibility screening is different, but the underlying concept is similar: high-volume review + repeatable decision criteria.
In intake, AI is increasingly used to:
- Extract structured facts from unstructured text (medical records, pharmacy printouts, incident narratives)
- Detect missing fields and inconsistencies (timeline gaps, dosage conflicts, missing diagnosis documentation)
- Classify likely eligibility (e.g., “meets core criteria,” “needs more records,” “likely ineligible”)
- Route cases to the right next step (records request, nurse review, attorney review, or close-out)
Think of AI as a force multiplier for your reviewers: it handles the repetitive first-pass organization so human experts spend more time on judgment calls.
2) Eligibility screening is becoming a “workflow,” not a moment
The best AI-enabled screening isn’t a single model output. It’s a workflow with checkpoints, because eligibility often emerges over time as records arrive.
A modern approach looks like this:
Step A: First-pass triage (minutes)
- Normalize claimant narratives into a structured intake summary
- Identify obvious disqualifiers or missing essentials
- Assign a provisional status and next action
Step B: Evidence enrichment (hours to days)
- Trigger targeted records requests based on what’s missing
- Extract key medical facts when documents are received
- Update the eligibility score and rationale
Step C: Human validation and decisioning
- Reviewer confirms the key facts AI extracted
- Final eligibility decision is recorded with reasons and supporting documents
This matters because the biggest operational win isn’t just speed, it’s consistency. Two reviewers shouldn’t reach opposite conclusions due to fatigue, time pressure, or incomplete visibility.
3) Why “proportionality” thinking shows up here, too
Federal discovery rules have increasingly emphasized efficiency and proportionality—most notably through the December 1, 2015 amendments that promoted “proportional discovery” and cost containment.
Intake has its own version of proportionality:
- Not every lead deserves the same depth of review immediately.
- Your process should reserve the most expensive human time for the most viable cases.
- The earlier you identify “needs more info” vs. “strong fit,” the better your economics.
AI can support that proportional approach by triaging intelligently and tightening your “time-to-clarity.”
4) Where AI helps most (and where it can hurt)
High-confidence wins
AI tends to perform well when tasks are:
- Repetitive and pattern-based (dates, diagnoses, product names)
- Supported by consistent document types (standard medical record formats, pharmacy reports)
- Evaluated against clear criteria (time windows, documented diagnosis, exposure thresholds)
Common failure modes to plan for
AI can create risk when:
- Data inputs are messy (handwritten notes, incomplete PDFs, inconsistent nomenclature)
- Criteria are fuzzy (edge cases, evolving causation theories, multi-factor eligibility)
- The system lacks provenance (no traceability for what it relied on)
- Automation bias creeps in (reviewers over-trust a model label)
This is why responsible AI guidance increasingly focuses on risk management and operational controls. For cross-sector AI risk practices, many organizations reference frameworks like the NIST AI Risk Management Framework (AI RMF 1.0) (released January 26, 2023).
You don’t need a compliance theater program to benefit from this. You need clear controls.
5) The “defensibility stack”: controls that make AI-driven screening usable
If your firm is relying on AI-assisted review in intake, you want a defensibility stack that includes:
1) Transparent criteria
- Encode eligibility rules in plain language
- Keep version history when criteria change
2) Audit trails
- Log what documents were reviewed and what facts were extracted
- Preserve reviewer overrides and rationale
3) Quality assurance sampling
- Regularly sample AI-labeled “eligible” and “ineligible” cases
- Track error categories (missing docs, wrong dates, misread diagnosis)
4) Human-in-the-loop checkpoints
- Require human validation for final eligibility decisions
- Define which edge cases must escalate to attorney review
5) Data governance basics
- Minimize data intake to what’s needed
- Control access, retention, and vendor data usage
Done well, AI doesn’t just make intake faster, it makes it cleaner, more consistent, and more scalable when campaigns ramp.
6) What to ask before you scale AI eligibility screening
When evaluating vendors, intake partners, or internal tooling, ask:
- What exactly is automated vs. assisted? (What decisions are model-driven? What decisions require human confirmation?)
- How do you measure accuracy? (Precision/recall, error types, performance on edge cases)
- How do you handle missing records? (Does the workflow prompt targeted records requests?)
- What’s the audit trail? (Can you reconstruct why a case was routed a certain way?)
- How do criteria updates work? (Versioning, change control, rollout testing)
- What data does the model retain or learn from? (Privacy, reuse, retention)
- How do you prevent “automation bias”? (Reviewer training, QA sampling, escalation rules)
These answers will determine whether AI becomes a sustainable advantage, or a fragile bottleneck you can’t fully trust.
turning AI into a growth lever (not just an ops tool)
AI-enabled intake is no longer just a back-office efficiency play. It directly affects growth: faster response times, better screening consistency, and a tighter feedback loop between marketing, intake, and case outcomes.
We are SmashOrbit Legal. We are a complete client acquisition partner with decades of experience from top plaintiffs firms and Fortune 500 brand advertising. We use AI analysis to continuously refine channels and optimize campaigns so firms get more consistent volume of higher qualified claimants.
Contact Us Today!